Jan 06, 2015 7:15am EST Can-Fite Announces Upcoming 2015 Clinical Milestones for its Pipeline of Drugs in 4 Indications
Dec 30, 2014 7:00am EST Can-Fite Completes the Design of the Rheumatoid Arthritis Phase III Study of Its Lead Drug Candidate CF101
Dec 15, 2014 7:02am EST Second Part of the Glaucoma Phase II study has been Approved in a European Country
Dec 09, 2014 7:00am EST Can-Fite to Initiate the Development Program of its Next Generation Drug CF602
Dec 01, 2014 7:00am EST US Researchers Published Scientific Findings that are a Potential Breakthrough for Prevention of Neuropathic Pain by CF101
Nov 17, 2014 5:48pm EST Can-Fite Announces Special General Meeting of Shareholders to Elect External Director
